- Acetylcholine is a major neurotransmitter in the brain1
- In patients with AD, cholinergic neurons are progressively lost, reducing levels of acetylcholine1
- ChEIs target cholinesterase enzymes (AChE and BuChE) and inhibit the breakdown of acetylcholine.1-3This increases the availability of acetylcholine at the cholinergic synapses.1,2
- Currently available FDA-approved ChEIs for the treatment of mild, moderate and severe AD are donepezil, rivastigmine, and galantamine1
Acess our Slide Deck on Treatment principles of Alzheimer’s disease (AD) and learn more about treatment with cholinesterase inhibitors.
Related content
The physical and social exposome in brain health and dementia across the lifespan
Social and physical exposome factors—like poverty, pollution, and inequality—accumulate over time, shaping biological aging and cognitive decline. Through inflammation and cellular stress, these exposures drive neurodegeneration, highlighting the need for longitudinal, integrative research.
12.11.2025
Alzheimer’s Disease
The Physical and Social Exposome in Brain Health and Dementia
The exposome reframes dementia as the product of cumulative physical and social exposures-like pollution, nutrition, and inequality-across life. These factors shape brain aging through inflammation and epigenetic change. Lifespan, global studies are key to equitable dementia prevention.
12.11.2025
Alzheimer’s Disease
